Latest news with #Cambridge
Yahoo
4 hours ago
- General
- Yahoo
Tiger moth finds new home at WW2 airfield museum
A Tiger Moth has found a new home at an airfield where dozens of the aeroplanes were used to train pilots during World War Two. The biplane has been donated to the Bottisham Airfield Museum, near Cambridge, by the Imperial War Museum in Duxford. Jason Webb, chair of the airfield's trustees, said he was delighted about the donation, adding Tiger Moths were "top of our wanted list of exhibits". This type of aircraft was "the first to land at Bottisham in 1940 and the last to take off in 1946", he said. It will go on display at the museum for the first time on Sunday. Mr Webb said: "We became aware about six months ago that the Imperial War Museum was disposing of it as part of its reorganisation and put a bid in for it - alongside other museums - and they kindly selected ourselves out of all the others." The grass airfield at Bottisham was built in 1940 as a satellite for RAF Waterbeach and was initially used by Cambridge-based Tiger Moths from Marshalls (airfield) as a relief landing ground. The aircraft remained a regular sight in the skies over RAF Bottisham until 1946, serving with the RAF, the USAAF and the RAF Belgian section. Mr Webb said: "De Havilland Tiger Moths were elementary training aircraft, used to teach tens of thousands of pilots to fly, before they went on to fly Lancaster [bombers] or Spitfire [fighter aeroplanes]. "We want to put it on display to tell the story of pilots who flew them." In particular, he said he wanted to focus on the Tiger Moth's little-known role in Operation Banquet Lights, where the aircrafts were fitted with bombs just in case the Germans invaded England in 1940. "Luckily, this was not needed as it would have been a one-way trip for the pilots against modern German fighters," he added. Follow Cambridgeshire news on BBC Sounds, Facebook, Instagram and X. Anniversary flight for 99-year-old RAF veteran Memorials planned for disused WW2 airfields The untold story of the battle that helped end WW2 in Europe WW2 plane's engine restored to honour RAF crew World War Two veteran celebrates 105th birthday Bottisham Airfield Museum
BBC News
5 hours ago
- General
- BBC News
Tiger Moth finds new home at Bottisham's WW2 airfield museum
A Tiger Moth has found a new home at an airfield where dozens of the aeroplanes were used to train pilots during World War Two. The biplane has been donated to the Bottisham Airfield Museum, near Cambridge, by the Imperial War Museum in Webb, chair of the airfield's trustees, said he was delighted about the donation, adding Tiger Moths were "top of our wanted list of exhibits".This type of aircraft was "the first to land at Bottisham in 1940 and the last to take off in 1946", he said. It will go on display at the museum for the first time on Sunday. Mr Webb said: "We became aware about six months ago that the Imperial War Museum was disposing of it as part of its reorganisation and put a bid in for it - alongside other museums - and they kindly selected ourselves out of all the others." The grass airfield at Bottisham was built in 1940 as a satellite for RAF Waterbeach and was initially used by Cambridge-based Tiger Moths from Marshalls (airfield) as a relief landing aircraft remained a regular sight in the skies over RAF Bottisham until 1946, serving with the RAF, the USAAF and the RAF Belgian section. Mr Webb said: "De Havilland Tiger Moths were elementary training aircraft, used to teach tens of thousands of pilots to fly, before they went on to fly Lancaster [bombers] or Spitfire [fighter aeroplanes]. "We want to put it on display to tell the story of pilots who flew them."In particular, he said he wanted to focus on the Tiger Moth's little-known role in Operation Banquet Lights, where the aircrafts were fitted with bombs just in case the Germans invaded England in 1940."Luckily, this was not needed as it would have been a one-way trip for the pilots against modern German fighters," he added. Follow Cambridgeshire news on BBC Sounds, Facebook, Instagram and X.
Yahoo
6 hours ago
- Health
- Yahoo
Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE
mNEXSPIKE becomes Moderna's third FDA-approved product CAMBRIDGE, MA / / May 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mNEXSPIKE® (mRNA-1283), a new vaccine against COVID-19, for use in all adults 65 and older, as well as individuals aged 12-64 years with at least one or more underlying risk factor as defined by the Centers for Disease Control and Prevention (CDC).[1] "The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19," said Stéphane Bancel, Chief Executive Officer of Moderna. "COVID-19 remains a serious public health threat, with more than 47,000 Americans dying from the virus last year alone. We appreciate the FDA's timely review and thank the entire Moderna team for their hard work and continued commitment to public health." The FDA's approval of mNEXSPIKE is based on results from a randomized, observer-blind, active-controlled Phase 3 clinical trial ( Identifier: NCT05815498), which enrolled approximately 11,400 participants aged 12 years and older. The primary efficacy objective in this study was to demonstrate the non-inferior vaccine efficacy against COVID-19 starting 14 days after mNEXSPIKE compared to that after the comparator vaccine, mRNA-1273 (Spikevax®), Moderna's original COVID-19 vaccine. Participants received either a 10 μg dose of mRNA-1283 or a 50 μg dose of mRNA-1273. mRNA-1283 showed a 9.3% higher relative vaccine efficacy (rVE) compared to mRNA-1273 in individuals aged 12 years and older, and in a descriptive sub-group analysis, a 13.5% higher rVE in adults aged 65 and older. In the Phase 3 trial, mRNA-1283 was found to have a similar safety profile to mRNA-1273, with fewer local reactions and comparable systemic reactions. The most commonly solicited side effects were injection site pain, fatigue, headache and myalgia. Moderna expects to have mNEXSPIKE available for eligible populations in the U.S. for the 2025-2026 respiratory virus season, alongside Spikevax and mRESVIA®, the Company's approved respiratory syncytial virus (RSV) vaccine. mRNA-1283 is under review with regulators in multiple markets around the world. About ModernaModerna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. mNEXSPIKE®, mRESVIA® and Spikevax®are registered trademarks of Moderna. INDICATION mNEXSPIKE is a vaccine to protect against COVID-19. mNEXSPIKE is for people who have received a COVID-19 vaccine before and are: • 65 years of age and older, or • 12 years through 64 years of age at high risk for severe COVID-19. Vaccination with mNEXSPIKE may not protect all people who receive the vaccine. IMPORTANT SAFETY INFORMATION You should not get mNEXSPIKE if you hada severe allergic reaction after a previous dose of either mNEXSPIKE, SPIKEVAX (COVID-19 Vaccine, mRNA), or any Moderna COVID-19 vaccine or to any ingredient in these vaccines. What are the risks of mNEXSPIKE?There is a very small chance that mNEXSPIKE could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to 1 hour after getting a dose of mNEXSPIKE. For this reason, your healthcare provider may ask you to stay for a short time at the place where you received your vaccine. Signs of a severe allergic reaction can include: Trouble breathing Swelling of your face and throat A fast heartbeat A rash all over your body Dizziness and weakness Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received mRNA COVID-19 vaccines. Myocarditis and pericarditis following mRNA COVID-19 vaccines have occurred most commonly in males 12 years through 24 years of age. You should seek medical attention right away if you or your child has any of the following symptoms after receiving the vaccine, particularly during the 2 weeks after receiving a dose of the vaccine: Chest pain Shortness of breath Feelings of having a fast-beating, fluttering, or pounding heart Side effects that have been reported in clinical trials with mNEXSPIKE include: Injection site reactions: pain, tenderness and swelling of the lymph nodes in the same arm of the injection, swelling (hardness), and redness. General side effects: fatigue, headache, muscle pain, joint pain, chills, nausea, vomiting, and fever Tell your vaccination provider about all of your medical conditions, including if you: have any allergies had a severe allergic reaction after receiving a previous dose of any COVID-19 vaccine have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart) have a fever have a bleeding disorder or are on a blood thinner are immunocompromised or are on a medicine that affects your immune system are pregnant or plan to become pregnant are breastfeeding have received any other COVID-19 vaccine have ever fainted in association with an injection These may not be all the possible side effects of mNEXSPIKE. Ask your healthcare provider about any side effects that concern you. You may report side effects to Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967 or Please click for mNEXSPIKE Full Prescribing Information. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the efficacy, safety and tolerability of mNEXSPIKE; and the availability of Moderna's respiratory vaccines for the 2025-2026 season. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release. Moderna ContactsMedia:Chris RidleyHead of Global Media Relations+1 Investors:Lavina TalukdarSenior Vice President & Head of Investor Relations+1 [1] SOURCE: Moderna, Inc. View the original press release on ACCESS Newswire Sign in to access your portfolio
Express Tribune
6 hours ago
- Politics
- Express Tribune
NA panel to probe CIE paper leaks
The National Assembly Standing Committee on Education has expressed lack of confidence in the Cambridge examination system and decided to investigate the alleged leak of papers during the recent CIE exams. The committee — which met with MNA Azeem Zahid in the chair — expressed serious concerns over the declining credibility of CIE in Pakistan due to repeated incidents of paper leaks. Muhammad Ali Sarfraz, an MNA from Faisalabad, shared purported video evidence provided by students that allegedly confirms the leak of papers from the May 2025 O and A Level exam series. While the malpractice may have benefitted only a small group of students, Cambridge's response — either cancelling exams or relying on average-based grading — could unfairly penalise a large number of students. He urged Cambridge to consider re-administering the affected papers or adjusting the grade thresholds. The committee also questioned the oversight mechanism for CIE in Pakistan. A representative from the Ministry of Federal Education clarified that the ministry does not regulate Cambridge assessments, placing responsibility with the Inter Board Committee of Chairmen (IBCC). However, IBCC Executive Director Dr Ghulam Ali Malah said that he had not been formally assigned any such oversight responsibility. He revealed that authorisation had previously been granted — without IBCC consultation — to allow Cambridge exams to be conducted by private schools in addition to the British Council. Dr Malah referred to a similar incident last year, when a paper was cancelled due to a leak, Cambridge failed to share the results of its internal investigation with IBCC. Instead, the committee learnt of the developments through legal notices. In the end, the committee decided to set up a subcommittee to independently investigate the leaks. The subcommittee comprises Dr Aleem, Zaib Jaffar, Muhammad Ali Sarfraz, and Dr Ghulam Ali Malah. It has been tasked with reviewing the circumstances of the exam breaches and, if required, will seek to engage with Cambridge representatives based abroad due to the limited mandate of local officials, including Cambridge's Pakistan representative, Uzma Yousaf. The investigation is scheduled to begin after June 16, following a request from Yousaf. During the meeting, she attempted to shift attention by criticising the performance of Pakistani education boards, suggesting that many students opt for Cambridge due to their shortcomings. However, committee members rebuffed her remarks, saying that not all Pakistani boards perform poorly and that her focus should remain on addressing the issues within the Cambridge system. The committee reaffirmed its commitment to ensuring fairness and transparency in academic assessments and stressed the importance of protecting students from the consequences of administrative lapses.
Washington Post
7 hours ago
- General
- Washington Post
Federal officials to vet social media accounts of visa applicants heading to Harvard
Federal officials are set to start reviewing the social media accounts of visa applicants who plan to attend, work at or visit Harvard University for any signs of antisemitism, marking the latest development in a clash between the Trump administration and the Ivy League school. A cable sent Friday signed by Secretary of State Marco Rubio and obtained by The Associated Press accused the university of failing to keep violence and antisemitism off campus. It said the vetting measure will help consular officers identify applicants with a history of those offenses 'and to duly consider their visa eligibility under U.S. immigration law.'
